The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 30, 2019
Filed:
Dec. 28, 2015
Applicants:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Novartis Ag, Basel, CH;
Inventors:
Felipe Bedoya, East Norristown, PA (US);
Saba Ghassemi, Philadelphia, PA (US);
Carl H. June, Merion Station, PA (US);
Bruce L. Levine, Cherry Hill, NJ (US);
Jan J. Melenhorst, Cherry Hill, MA (US);
Michael C. Milone, Cherry Hill, NJ (US);
Daniel J. Powell, Jr., Bala Cynwyd, PA (US);
Zoe Zheng, Cherry Hill, NJ (US);
Assignees:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/705 (2006.01); C12N 9/12 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 35/17 (2015.01); C12N 5/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C12N 5/0087 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/1276 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/14 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2510/00 (2013.01); C12Y 207/07049 (2013.01);
Abstract
The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.